Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer.

Wieke C H VisserHans de JongSandra SteyaertWillem J G MelchersPeter F A MuldersJack A Schalken

Published in: Prostate cancer and prostatic diseases (2022)

The potential number of reduced biopsies in clinical use was 40,72% using the SelectMDx test, assuming a negative SelectMDx test resulted in the decision not to biopsy the patient. This is higher compared to the validation cohort, which is explained by differences in patient population.

Keyphrases

prostate cancer
case report
ultrasound guided
radical prostatectomy
risk assessment
climate change
human health